Xeris Biopharma Holdings, Inc. (XERS)

NASDAQ: XERS · Real-Time Price · USD

8.48

-0.12 (-1.40%)

At close: Aug 28, 2026, 4:00 PM EDT

8.60

+0.12 (1.42%)

After-hours: Aug 28, 2026, 7:57 PM EDT

Xeris Biopharma Holdings Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	121.75	111.04	71.62	67.45	121.97	67.27
Short-Term Investments	-	-	-	5	-	35.16
Cash & Short-Term Investments	121.75	111.04	71.62	72.45	121.97	102.43
Cash Growth	105.36%	55.04%	-1.15%	-40.60%	19.07%	-23.44%
Accounts Receivable	58.11	51.05	40.42	39.2	30.83	17.46
Receivables	58.11	51.05	40.42	39.2	30.83	17.46
Inventory	80.93	68.67	48.18	38.84	24.74	18.12
Prepaid Expenses	13.98	9.55	7.45	5.78	9.29	4.59
Total Current Assets	274.76	240.31	167.66	156.26	186.82	142.6
Property, Plant & Equipment	26.61	27.06	28.21	29.18	9.51	6.63
Goodwill	22.86	22.86	22.86	22.86	22.86	22.86
Other Intangible Assets	82.66	88.08	98.92	109.76	120.61	131.45
Other Long-Term Assets	5.03	5.22	5.41	4.54	4.73	0.83
Total Assets	411.91	383.53	323.06	322.6	344.52	304.36

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Accounts Payable	9.34	3.08	2.29	11.57	4.61	8.92
Accrued Expenses	86.56	76.41	56.8	45.66	44.09	51.17
Current Portion of Long-Term Debt	63.78	-	15.1	-	-	-
Current Portion of Leases	6.31	6.23	6.08	3.5	1.58	-
Other Current Liabilities	23.57	23.86	20.17	34.47	23.35	18.95
Total Current Liabilities	189.57	109.57	100.44	95.19	73.62	79.04
Long-Term Debt	188.81	220.34	217.01	190.93	187.08	88.07
Long-Term Leases	30.54	31.53	33.26	34.76	9.4	-
Long-Term Deferred Tax Liabilities	-	-	-	2.27	3.52	4.94
Other Long-Term Liabilities	12.72	8.4	1.97	6.23	25.72	37.08
Total Liabilities	421.64	369.84	352.68	329.38	299.34	209.13

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Common Stock	0.02	0.02	0.02	0.01	0.01	0.01
Additional Paid-In Capital	690.43	685	642.26	610.25	599.97	555.36
Retained Earnings	-700.17	-671.31	-671.86	-617.03	-554.77	-460.11
Comprehensive Income & Other	-0.01	-0.03	-0.03	-0.03	-0.02	-0.03
Total Common Equity	-9.73	13.69	-29.62	-6.78	45.19	95.23
Shareholders' Equity	-9.73	13.69	-29.62	-6.78	45.19	95.23
Total Liabilities & Equity	411.91	383.53	323.06	322.6	344.52	304.36

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Total Debt	289.44	258.1	271.45	229.19	198.06	88.07
Net Cash (Debt)	-167.7	-147.06	-199.83	-156.74	-76.09	14.37
Net Cash Growth	-	-	-	-	-	-69.28%
Net Cash Per Share	-1.00	-0.85	-1.36	-1.14	-0.56	0.18
Filing Date Shares Outstanding	182.32	172.43	153.94	140.45	137.29	135.52
Total Common Shares Outstanding	173.59	166.22	149.43	138.13	136.27	124.87
Working Capital	85.19	130.74	67.22	61.07	113.2	63.56
Book Value Per Share	-0.06	0.08	-0.20	-0.05	0.33	0.76
Tangible Book Value	-115.25	-97.25	-151.4	-139.41	-98.28	-59.08
Tangible Book Value Per Share	-0.66	-0.59	-1.01	-1.01	-0.72	-0.47
Machinery	7.18	6.91	6.26	5.65	5.68	5.43
Leasehold Improvements	5.7	5.7	6.06	5.98	5.07	5.03

SEC Filings: 10-K · 10-Q